BIOA news

Latest 1 stories · newest Aug 5, 2026

BIOA

BioAge Reports Q2 2026 Results, Doses First Participant in BGE-102 Phase 2 Trial

BioAge Labs dosed the first participant in its Phase 2 trial of BGE-102 and plans to initiate a proof-of-concept trial for diabetic macular edema, signaling progress in its NLRP3 inhibition strategy.

Earnings Aug 5, 2026 sentiment +1.00 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same BIOA feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/BIOA/newsSTART FREE